GPT and susceptibility to pneumonia measurement: Specifically, as exhibited in Table 3, the common adverse reactions manifested as fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (HFS, 38.5%), rash (28.2%), AST/ALT elevation (25.6%), proteinuria (20.5%), weight loss (17.9%), reactive cutaneous capillary endothelial proliferation (RCCEP, 15.4%), pneumonia (10.3), and anemia (7.7%).